Back to Search
Start Over
Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?
- Source :
-
Aging [Aging (Albany NY)] 2023 Jul 20; Vol. 15 (14), pp. 6632-6640. Date of Electronic Publication: 2023 Jul 20. - Publication Year :
- 2023
-
Abstract
- Both individuals taking rapamycin, an anti-aging drug, and those not taking it will ultimately succumb to age-related diseases. However, the former, if administered disease-oriented dosages for a long time, may experience a delayed onset of such diseases and live longer. The goal is to delay a particular disease that is expected to be life-limiting in a particular person. Age-related diseases, quasi-programmed during development, progress at varying rates in different individuals. Rapamycin is a prophylactic anti-aging drug that decelerates early development of age-related diseases. I further discuss hyperfunction theory of quasi-programmed diseases, which challenges the need for the traditional concept of aging itself.
- Subjects :
- Humans
Aging
Longevity
Sirolimus pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1945-4589
- Volume :
- 15
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Aging
- Publication Type :
- Academic Journal
- Accession number :
- 37477535
- Full Text :
- https://doi.org/10.18632/aging.204920